This is another comment just came out : DJ From Sandalwood to...

This is another comment just came out :

	Column 1	Column 2	Column 3	Column 4	Column 5
0	DJ From Sandalwood to Wart Removal, TFS's Outlook Is Bright -- Market Talk	Column 1 0 TFC		$1.53-$0.01 (-0.6%)	$1.53$1.57

	Column 1	Column 2
0		01 Sep 2015 10:44:57

	Column 1	Column 2
0	1 View	0 comments

Column 1

0

0044 GMT [Dow Jones] There are plenty of reasons to think sandalwood producer TFS's (TFC.AU) shares can move higher, says UBS, which lifts its price target by 7.7% to A$2.80/share. "TFS's assets offer long-dated cash flows," analyst Jordan Rogers says. "However, we believe there are potential positive catalysts over the coming 6-18 months in the form of production volumes ramping up, and new pharmaceutical product launches." The broker says feedback from TFS's first pharmaceutical product--namely, the Benzac acne treatment by Galderma--is likely before the end of December. Also, treatments for eczema and skin warts are likely. "Should new pharmaceutical products offer long-term pricing contracts (like acne), we believe TFS would be significantly de-risked as an investment," Rogers says. UBS rates TFS at buy. The stock last traded at A$1.55. ([email protected]; Twitter: @dwinningWSJ) Editor JSM(END) Dow Jones Newswires August 31, 2015 20:44 ET (00:44 GMT)

[/table]